| Company Name |
Date |
Type |
Amount Raised (Mil) |
Investors in round |
Stage at Funding |
Primary Therapeutic Area |
Primary Tech |
Article |
| Tmunity Therapeutics Inc. |
10.31.19 |
Series B |
$75.00 |
Andreessen Horowitz, Gilead Sciences Inc., University of Pennsylvania, BrightEdge (American Cancer Society) |
01 Platform / Discovery |
Cancer |
Immunotherapy / Cell Therapy |
Link |
| LyGenesis Inc. |
10.21.19 |
Convertible Loan |
$4.00 |
Juvenescence Ltd. |
02 Preclinical / IND |
Other |
Immunotherapy / Cell Therapy |
Link |
| MEBIAS Discovery LLC |
10.14.19 |
Unspecified |
$3.50 |
Viva Biotech Ltd. |
02 Preclinical / IND |
Neurologic |
Small Molecule |
|
| Galera Therapeutics Inc. |
10.11.19 |
IPO |
$80.00 |
– |
05 Phase III |
Cancer |
Small Molecule |
Link |
| Cabaletta Bio Inc. |
9.30.19 |
Common |
$74.80 |
– |
02 Preclinical / IND |
Autoimmune |
Immunotherapy / Cell Therapy |
Link |
| AIM ImmunoTech Inc. (formerly Hemispherx Biopharma) |
9.25.19 |
Common |
$8.00 |
– |
06 Approved |
Infectious |
Small Molecule |
Link |
| Lannett Co. Inc. |
9.24.19 |
Convertible Notes |
$86.25 |
– |
06 Approved |
Not Applicable |
Small Molecule |
Link |
| Onconova Therapeutics Inc. |
9.23.19 |
Common |
$3.40 |
– |
05 Phase III |
Cancer |
Not Applicable |
Link |
| Navrogen Inc. |
9.17.19 |
Convertible Notes |
$3.20 |
Ben Franklin Technology Partners |
08 Diagnostic – Any |
Cancer |
Diagnostic – Lab Based Assay |
Link |
| Onconova Therapeutics Inc. |
9.13.19 |
Common |
Undisclosed |
– |
05 Phase III |
Cancer |
Not Applicable |
Link |
| Renovacor Inc. |
8.14.19 |
Series A |
$11.00 |
BioAdvance, Broadview Ventures Inc., New Leaf Venture Partners, Innogest, Novartis Venture Fundr |
02 Preclinical / IND |
Cardiovascular |
Gene Therapy |
Link |
| Ilera Healthcare LLC |
8.02.19 |
Series Unspecified |
$25.00 |
– |
06 Approved |
Not Applicable |
Other Tech |
|
| Century Therapeutics |
7.01.19 |
Series Unspecified |
$250.00 |
Versant Ventures, Cellular Dynamics International Inc. (Fujifilm), Leaps by Bayer |
01 Platform / Discovery |
Cancer |
Immunotherapy / Cell Therapy |
Link |
| Krystal Biotech Inc. |
6.24.19 |
Common |
$100.00 |
– |
09 Not Disclosed |
Dermatologic |
Gene Therapy |
Link |
| Intact Vascular |
5.29.19 |
Undisclosed |
$25.00 |
– |
07 Device – Any |
Other |
Device (General) |
Link |
| Vesper Medical |
5.29.19 |
Undisclosed |
$37.00 |
– |
09 Not Disclosed |
Unknown |
Unknown |
|
| PhaseBio Pharmaceuticals Inc. |
4.11.19 |
Common |
$43.00 |
– |
04 Phase II |
Not Applicable |
Formulation – Other |
Link |
| Noveome Biotherapeutics Inc. |
4.09.19 |
Series D |
$15.00 |
– |
04 Phase II |
Dermatologic |
Small Molecule |
Link |
| PhaseBio Pharmaceuticals Inc. |
3.25.19 |
Debt/Loan |
$7.50 |
– |
04 Phase II |
Not Applicable |
Formulation- Other |
Link |
| Harmony Biosciences LLC |
3.13.19 |
Debt/Loan |
$200.00 |
– |
09 Not Disclosed |
Neurologic |
Other Tech |
|
| NeuBase Therapeutics Inc. (Ohr Pharmaceutical) |
3.11.19 |
Common |
$9.00 |
– |
09 Not Disclosed |
Neurologic |
Gene Therapy |
Link |
| Geneos Therapeutics Inc. |
2.21.19 |
Series A |
$10.50 |
– |
09 Not Disclosed |
Neurologic |
Gene Therapy |
Link |
| Passage Bio Inc. |
2.14.19 |
Series A |
$115.50 |
OrbiMed Advisors LLC, Frazier Healthcare Partners, Versant Ventures, New Leaf Venture Partners, Vivo Capital LLC, Lilly Asia Ventures |
09 Not Disclosed |
Neurologic |
Gene Therapy |
Link |
| Inovia Pharmaceuticals Inc. |
2.13.19 |
Convertible Note |
$65.00 |
– |
04 Phase II |
Infectious |
N/A |
Link |
| Trevena Inc. |
1.30.19 |
Common |
$10.00 |
– |
05 Phase IIII |
Neurologic |
Small Molecule |
Link |
| Aro Biotherapeutics Co. |
12.11.18 |
Undisclosed |
$13.00 |
– |
09 Not Disclosed |
Cancer |
Protein |
Link |
| Marinus Pharmaceuticals Inc. |
12.11.18 |
Common |
$45.00 |
– |
04 Phase II |
Neurologic |
Not Applicable |
Link |
| XyloCor Therapeutics Inc. |
12.06.18 |
Series A |
$17.00 |
Sofinnova Ventures Inc. Life Sciences Partners |
03 Phase I |
Cardiovascular |
Gene Therapy |
Link |
| Helius Medical Technologies |
11.14.18 |
Common |
$17.50 |
– |
07 Device – Any |
Neurologic |
Device (General) |
|
| Cabaletta Bio Inc. |
11.08.18 |
Series A |
$38.50 |
5AM Ventures, Adage Capital Management L.P., University of Pennsylvania |
02 Preclinical / IND |
Autoimmune |
Immunotherapy / Cell Therapy |
Link |
| Group K Diagnostics Inc. |
10.31.18 |
Series A |
$2.00 |
– |
07 Device – Any |
Not Applicable |
Device (General) |
|
| Aclaris Inc. |
10.15.18 |
Debt / Loan |
$30.00 |
Oxford Finance LLC |
05 Phase III |
Dermatologic |
Small Molecule |
Link |
| PhaseBio Pharmaceuticals Inc. |
09.21.18 |
IPO |
$46.00 |
– |
04 Phase II |
Not Applicable |
Formulation – Other |
Link |
| Galera Therapeutics Inc. |
09.19.18 |
Series C |
$70.00 |
Clarus Ventures LLC, Adage Capital Management L.P., HBM Healthcare Investments Ltd., Nan Fung Life Sciences, RA Capital Management LLC, Rock Springs Capital LP, Tekla Capital Management (formerly H&Q Capital Management), Correlation Ventures, Galera Angels, New Enterprise Associates, Novartis Venture Fund, Novo Ventures (Novo Holdings A/S), Sofinnova Ventures Inc. |
04 Phase II |
Cancer |
Small Molecule |
Link |
| PhaseBio Pharmaceuticals Inc. |
09.05.18 |
Series D |
$34.00 |
Cormorant Asset Management LLC, Rock Springs Capital LP, Mountain Group Capital, New Enterprise Associates, Hatteras Venture Partners, AstraZeneca plc, Johnson & Johnson Innovation – JJDC Inc., Syno Capital, Fletcher Spaght Ventures |
04 Phase II |
Not Applicable |
Small Molecule |
Link |
| Aevi Genomic Medicine Inc. |
08.21.18 |
Common |
$4.90 |
– |
04 Phase II |
Neurologic |
Small Molecule |
Link |
| Krystal Biotech |
08.16.18 |
Common |
$10.00 |
Frazier Healthcare Partners |
09 Not Disclosed |
Unknown |
Unknown |
Link |
| Fibrocell Science Inc. |
07.02.18 |
Common |
$3.96 |
– |
06 Approved |
Not Applicable |
Immunotherapy / Cell Therapy |
|
| Carisma Therapeutics Inc. |
06.27.18 |
Series A |
$53.00 |
AbbVie Ventures, HealthCap, IP Group plc, University of Pennsylvania, Grazia Equity, Wellington Partners, TPG, MRL Ventures Fund LLC, Agent Capital |
02 Preclinical / IND |
Cancer |
Immunotherapy / Cell Therapy |
Link |
| Neuronetics Inc. |
05.31.18 |
IPO |
$107.50 |
– |
07 Device – Any |
Neurologic |
Device (General) |
Link |
| Fibrocell Science Inc. |
05.29.18 |
Common |
$5.80 |
– |
06 Approved |
Not Applicable |
Immunotherapy / Cell Therapy |
|
| Hemispherx Biopharma Inc. |
04.20.18 |
Undisclosed |
Undisclosed |
– |
06 Approved |
Infectious |
Small Molecule |
|
| Carisma Therapeutics Inc. |
04.17.18 |
Debt / Loan |
$3.85 |
– |
01 Platform / Discovery |
Cancer |
Immunotherapy / Cell Therapy |
|
| TELA Bio Inc. |
04.17.18 |
Undisclosed |
Undisclosed |
Checkmate Capital |
07 Device – Any |
Gastrointestinal |
Device (General) |
Link |
| Intact Vascular Inc. |
04.16.18 |
Series C |
$20.00 |
New Enterprise Associates, H.I.G. BioVentures, Quaker Partners |
07 Device – Any |
Other |
Device (General) |
Link |
| Windtree Therapeutics Inc. |
04.04.18 |
Common |
$2.60 |
– |
07 Device – Any |
Pulmonary |
Device (General) |
Link |
| Helius Medical Technologies Inc. |
04.04.18 |
Common |
$18.40 |
– |
07 Device – Any |
Neurologic |
Device (General) |
Link |
| STRATA Skin Sciences Inc. |
04.02.18 |
Common |
$17.00 |
Broadfin Capital, Sabby Management |
07 Device – Any |
Dermatologic |
Device (General) |
Link |
| Tmunity Therapeutics Inc. |
01.23.18 |
Series A |
$100.00 |
Ping An Ventures, Parker Institute for Cancer Immunotherapy, Gilead Sciences Inc., Be The Match (National Marrow Donor Program), University of Pennsylvania, Lilly Asia Ventures |
01 Platform / Discovery |
Cancer |
Immunotherapy / Cell Therapy) |
Link |
| Strongbridge Biopharma Plc |
01.23.18 |
Common |
$35.47 |
– |
05 Phase III |
Endocrine / Metabolic |
Small Molecule |
|
| OptiNose Inc. |
01.02.18 |
Convertible Notes |
$75.00 |
Athyrium Capital Management |
06 Approved |
Pulmonary |
Small Molecule |
|
